When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
NEW YORK (Reuters Health) – Response rates are higher when bortezomib plus dexamethasone rather than vincristine plus doxorubicin plus dexamethasone (VAD) is used as induction therapy before stem-cell…
NEW YORK (Reuters Health) – Men whose baseline PSA is less than 2.0 ng/mL are unlikely to benefit from further screening for prostate cancer, according to findings reported…
NEW YORK (Reuters Health) – A finding of homozygosity for mutations that cause Gaucher disease in patients who report no symptoms of the disorder warrants further followup. Manifestations…
NEW YORK (Reuters Health) – HER2 protein and gene expression predict the response of breast cancer patients to adjuvant trastuzumab therapy, but which test provides the best information?…
NEW YORK (Reuters Health) – Rates of clearance of high-grade anal canal intraepithelial neoplasia in men with HIV are improved considerably by topical application of imiquimod cream, a…
NEW YORK (Reuters Health) – Men undergoing androgen deprivation therapy for prostate cancer halve their risk of vertebral fractures if they take the selective estrogen receptor modulator toremifene…
NEW YORK (Reuters Health) – A Canadian study has identified several readily available clinical factors that help determine the risk of fractures in men with prostate cancer undergoing…
NEW YORK (Reuters Health) – The intensity of bortezomib-based regimens used to treat multiple myeloma in elderly patents can be reduced in order to lessen toxicity, without jeopardizing…
NEW YORK (Reuters Health) – Among adult patients being treated for hematologic malignancies and who are at high risk for tumor lysis syndrome with hyperuricemia, intravenous rasburicase does…
NEW YORK (Reuters Health) – Perioperative dexamethasone does not boost the risk of post-tonsillectomy hemorrhage, according to a large retrospective study reported in the August Archives of Otolaryngology…
